725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Susana Banerjee, Rafael Grochot, R. Shinde, João Paulo da Silveira Nogueira Lima, Matthew Krebs, R. Abdul Rahman, Martin Little, Nina Tunariu, Andra Curcean, Hannah Badham, Muneeb Mahmud, Alison Turner, Mona Parmar, Christina Yap, Anna Minchom, Juanita Lopez, Johann S. de Bono, Udai Banerji
Topics & Concepts
MedicineMEK inhibitorKRASAdverse effectInternal medicineResponse Evaluation Criteria in Solid TumorsOvarian cancerPharmacodynamicsOncologyCombination therapyPharmacokineticsPhases of clinical researchRashCancerChemotherapyGastroenterologyPharmacologyMAPK/ERK pathwayKinaseColorectal cancerCell biologyBiologyOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Mechanisms and Therapy